News

The drug’s favorable risk-benefit profile and sustained efficacy through 76 weeks was highlighted in this analysis’s findings.

In the complete response letter, the FDA classified deficiencies in the Abbreviated New Drug Application for ketamine as MINOR.

A study found people with schizophrenia have a 4-fold higher risk of sudden cardiac death compared to the general population, underscoring the need for cardiometabolic care.

Test your knowledge of the 2024 American College of Gastroenterology acute pancreatitis diagnosis and management guidelines with this clinical quiz!

Masri previewed data to be presented at the AHA 2024 Scientific Sessions and shared his excitement for the ongoing phase 3 trial of NTLA-2001.

This overview highlights our upcoming conference coverage at the Fall Clinical Dermatology Conference in Las Vegas.

A new study revealed patients with genetic variation of hCAZyme enzymes were more likely to reach success with low-carb diets to relieve IBS symptoms than those without.

Ustekinumab-aekn is set to enter the US market no later than February 21, 2025, as per a settlement and license agreement between Janssen, Teva, and Alvotech.

This analysis reconfirms the efficacy of dupilumab using a single-center design, a large sample size, and patients with chronic hand eczema.

Test your knowledge of the 2024 American College of Gastroenterology focal liver lesion diagnosis and management guidelines with this clinical quiz!

A study links hepatitis C infection and Parkinson's disease, identifying 19 genes with shared expression changes and highlighting sex-specific immune responses.

Decreasing Vitamin A dimerization could be a potential mechanism to treat geographic atrophy, according to results from the two-year SAGA study at AAO 2024.

Novo Nordisk will present more detailed data in 2025 and plans to file for an expanded label for Rybelsus for this population.

Pegcetacoplan injection showed increased benefit for subfoveal GA, with as few as 6 injections, over 3 years in the GALE extension trial.

Kidney Compass: Navigating Clinical Trials is a multimedia podcast from HCPLive hosted by Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, aimed at exploring the latest in clinical trials and updates in nephrology.

At AAO 2024, Pearlman discusses how an innovative oral approach may provide an alternative pathway to existing treatments for DME.

These data suggest more immediate benefits to alitretinoin, though ultraviolet therapy was shown to be cost-effective after 10 years of use.

Endophthalmitis incidence remained similar between face masking and non-face masking groups during anti-VEGF treatment.

A study found that adding depression to Life's Essential 8 provides minimal improvements in predicting cardiovascular and all-cause mortality risk.

Test your knowledge of the 2024 American College of Gastroenterology H. pylori management guidelines with this clinical quiz!

At AAO 2024, Goldberg described pooled visual function data from 3 randomized, controlled clinical trials evaluating NT-501 for patients with MacTel.

At AAO 2024, Borkar discusses the visual acuity benefit of ONL1204 ophthalmic solution for patients with macula-off rhegmatogenous retinal detachment.

TRS01 eye drops demonstrate a positive benefit-risk profile for potential use as a first-line treatment in anterior non-infectious uveitis.

Given the distrust some patients with conditions such as alopecia areata and psoriasis have regarding JAK inhibitors, this analysis highlights several approaches to such concerns.

The 24-month data showed a notable response rate in study eyes treated with a high dose of AGTC-501, with a generally safe and tolerable clinical profile.

At AAO 2024, Do describes the durable vision gains and anatomic improvements achieved with aflibercept 8 mg for DME over 3 years of the PHOTON trial.

A new meta-analysis found elevated triglyceride levels in patients with major depressive disorder, potentially explaining the link between depression and cardiovascular risks.

In the Phase 2 ARCHER trial, ANX007 protected against visual acuity loss and remained well-tolerated for patients with geographic atrophy.